Expression of HuR and Cyclooxygenase-2 in Nodular Fasciitis and Low- Grade Sarcoma: An Immunohistochemical Study

´ëÇѺ´¸®ÇÐȸÁö 2014³â 48±Ç 4È£ p.270 ~ p.275

¼ÕÇöÁø(Son Hyun-Jin) - Eulji University School of Medicine Department of Pathology
¹éÅÂÈ­(Baek Tae-Hwa) - Eulji University School of Medicine Department of Pathology
À̽ÂÀ±(Lee Seung-Yun) - Eulji University School of Medicine Department of Pathology
±èÁÖÇå(Kim Joo-Heon) - Eulji University School of Medicine Department of Pathology
°­µ¿¿í(Kang Dong-Wook) - Eulji University School of Medicine Department of Pathology
ÀÌÇý°æ(Lee Hye-Kyung) - Eulji University School of Medicine Department of Pathology
¹Ú¹ÌÀÚ(Park Mee-Ja) - Eulji University School of Medicine Department of Pathology

Abstract

Background: Nodular fasciitis is the most common reactive mesenchymal lesion to be misidentified as a type of sarcoma. HuR is an mRNA-binding protein that can stabilize cyclooxygenase-2 (COX-2) mRNA leading to COX-2 overexpression. The aim of this study is a comparison of the expressions of COX-2 and HuR and the relationships between their expressions and the clinicopathological parameters in nodular fasciitis and low-grade sarcoma.

Methods: We measured the expression of HuR and COX-2 in 21 cases of nodular fasciitis and 37 cases of low-grade sarcoma using immunohistochemistry.

Results: The frequency of cytoplasmic immunoreactivity for HuR was 5 of 21 cases of nodular fasciitis (23.8%) and 23 of 37 cases of low-grade sarcoma (62.1%) (p=.013). COX-2 expression was moderate or strong in nodular fasciitis (12/21, 57.1%) and in low-grade sarcoma (29/37, 78.4%) (p=.034). In addition, a significant difference existed between these two entities in terms of the relationship between moderate or strong COX-2 expression and HuR cytoplasmic immunoreactivity (p=.009). Moderate or strong COX-2 immunoreactivity correlated with nuclear (p=.016) or cytoplasmic HuR (p=.024) expression in low-grade sarcoma but not in nodular fasciitis.

Conclusions: This study suggests that HuR and COX-2 expression may be useful to differentiate nodular fasciitis from low-grade sarcoma.

Ű¿öµå

Nodular fasciitis, Sarcoma, Cyclooxygenase 2, HuR, Immunohistochemistry
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå